There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action. Annualized market revenues data for 9 key markets Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022 Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes.

1. PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022
There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet
needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking
because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.
Scope
Annualized market revenues data for 9 key markets Annualized market revenues data from 2012 to 2022 and
forecast from 2012 to 2022 Pipeline analysis data providing a split across the different phases, mechanisms of
action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major
therapeutic classes. Analysis of key recent licensing and partnership agreements in the PsO Therapeutics
market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently
researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor
assessment, market characterization, unmet needs and implications
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and
high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,
patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10
year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our
models support data presented in the reports and the complete methodology is outlined in the report and the
model.
*Model only available with site and global license purchases.
Key Findings
The global PsO therapeutics market is forecast to reach $7.61 billion by 2022 due to the launch of novel
pipeline drugs and biosimilars. All the leading branded biologics: Humira, Remicade, Stelara, and Enbrel, will
face the emergence of biosimilars as well as novel oral and injectable pipeline drugs. By 2022, PsO will be a
crowded marketplace comprising a highly diversified field of therapies with individual drugs struggling to
distinguish themselves.
Key Questions Answered in this Report
How will the patent expiry of Enbrel, Humira , Remicade, and Stelara affect the competitive landscape?
When will biosimilars emerge and how will they affect the market? What effect have changing regulations had
on companies investing in the sector? Who is the frontrunner in the drug pipeline for PsO and what are its
strengths and weaknesses? Will pipeline drugs be able to compete with the TNF inhibitors? Where are
companies investing R&D in 2013?
Key Benefits
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and
technologies and by identifying the companies with the most robust pipeline. Develop business strategies by
understanding the trends shaping and driving the global market. Drive revenues by understanding the key
trends, innovative products and technologies, market segments and companies likely to impact the market in
future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by
analyzing the performance of various competitors. Identify emerging players with potentially strong product
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

2. portfolios and create effective counter-strategies to gain a competitive advantage.
table Of Contents
1table Of Contents1
1.1list Of Tables5
1.2list Of Figures7
2executive Summary8
2.1sales For Psoriasis By Region 2012–20229
2.2research And Development And Corporate Strategies10
2.3unmet Needs In Psoriasis11
2.4new Entrant Opportunities11
2.5pipeline Agents And Future Landscape11
2.6what Do The Physicians Think?13
3introduction14
3.1catalyst14
3.2related Reports14
3.3upcoming Related Reports14
4disease Overview14
4.1etiology And Pathophysiology14
4.1.1etiology14
4.1.2pathophysiology16
4.2symptoms19
5epidemiology19
5.1risk Factors And Comorbidities19
5.1.1family History Of Psoriasis Increases The Risk Of Developing The Disease By Nearly 20 Times21
5.1.2obesity Doubles The Risk Of Psoriasis21
5.1.3smoking, Combined With Other Risk Factors, Increases The Risk For Psoriasis Up To Nine Times21
5.1.4psoriatic Arthritis Is Present In Up To 40.0% Of All Psoriasis Patients23
5.1.5nearly Half Of All Psoriasis Patients Report Elevated Stress Levels, Depression, And Thoughts Of
Suicide24
5.2global And Historical Trends25
5.2.1us25
5.2.25eu26
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

3. 5.2.3japan26
5.2.4china26
5.2.5india28
5.3forecast Methodology29
5.3.1sources Used29
5.3.2forecast Assumptions And Methods33
5.3.3sources Not Used37
5.4epidemiology Forecast (2012–2022)38
5.4.1prevalent Cases Of Psoriasis38
5.4.2age-specific Prevalent Cases Of Psoriasis40
5.4.3sex-specific Prevalent Cases Of Psoriasis42
5.4.4age-standardized Prevalence Of Psoriasis44
5.5discussion45
5.5.1conclusions On Epidemiology Trends45
5.5.2limitations Of The Analysis45
5.5.3strengths Of The Analysis47
6disease Management47
6.1treatment Overview48
6.2us 51
6.2.1diagnosis51
6.2.2clinical Practice52
6.3france54
6.3.1diagnosis54
6.3.2clinical Practice54
6.4germany56
6.4.1diagnosis56
6.4.2clinical Practice57
6.5italy 58
6.5.1diagnosis58
6.5.2clinical Practice58
6.6spain 60
6.6.1diagnosis60
6.6.2clinical Practice60
6.7uk 62
6.7.1diagnosis62
6.7.2clinical Practice62
6.8japan64
6.8.1diagnosis64
6.8.2clinical Practice64
6.9china66
6.9.1diagnosis66
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

4. 6.9.2clinical Practice66
6.10india 68
6.10.1diagnosis68
6.10.2clinical Practice68
7competitive Assessment69
7.1overview69
7.2strategic Competitor Assessment70
7.3product Profiles – Major Brands71
7.3.1enbrel (etanercept)71
7.3.2humira (adalimumab)78
7.3.3remicade (infliximab)83
7.3.4stelara (ustekinumab)89
7.3.5taclonex (calcipotriene Hydrate And Betamethasone Dipropionate)94
7.3.6methotrexate Sodium (numerous Generic Names)99
7.3.7minor Therapeutic Drug Classes Used In Psoriasis103
7.3.8non-pharmacological Therapy104
8opportunity And Unmet Need105
8.1overview105
8.2unmet Needs107
8.2.1improved Drug Safety And Efficacy Profiles107
8.2.2biomarkers For Predicting Remission107
8.2.3more Cost-effective Therapies Through Oral Formulation And Biosimilars108
8.2.4education And Treatment Of Psychological Factors Accompanying Psoriasis108
8.2.5an Effective Biologic/systemic Topical Therapy109
8.2.6more Effective Treatment For Mild Psoriasis, Specifically Uv Therapies109
8.2.7physician Education About The Different Types Of Psoriasis, Not Just Plaque Psoriasis109
8.3opportunities110
8.4unmet Needs Gap Analysis110
8.4.1predictive Tools For Diagnosis And Treatment111
8.4.2target Specificity111
8.4.3topical Biologic/systemic Therapeutic Options111
8.4.4helping Patients With Psychological Issues Associated With Psoriasis112
9pipeline Assessment112
9.1overview112
9.2clinical Trial Mapping113
9.2.1clinical Trials By Country113
9.3clinical Trials By Phase And Trial Status114
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

5. 9.4promising Drugs In Clinical Development115
9.4.1brodalumab (amg 827)117
9.4.2secukinumab (ain457)123
9.4.3ixekizumab (ly2439821)127
9.4.4tildrakizumab (mk-3222/sch-900222)133
9.4.5xeljanz (tofacitinib)138
9.4.6apremilast (cc-10004)144
9.4.7alzumab (itolizumab)150
9.4.8phase Ii Pipeline Products154
9.4.9phase I Pipeline Products155
9.4.10biosimilars Pipeline Products156
10current And Future Players158
10.1overview158
10.2trends In Corporate Strategy161
10.3company Profiles163
10.3.1amgen163
10.3.2abbvie (abbott)165
10.3.3johnson & Johnson167
10.3.4novartis169
10.3.5pfizer171
10.3.6eli Lilly173
10.3.7merck175
10.3.8leo Pharma177
10.3.9celgene179
11market Outlook180
11.1global Markets180
11.1.1forecast180
11.1.2drivers And Barriers – Global Issues186
11.2united States190
11.2.1forecast190
11.2.2key Events193
11.2.3drivers And Barriers193
11.3france196
11.3.1forecast196
11.3.2key Events199
11.3.3drivers And Barriers199
11.4germany201
11.4.1forecast201
11.4.2key Events204
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

6. 11.4.3drivers And Barriers204
11.5italy 206
11.5.1forecast206
11.5.2key Events209
11.5.3drivers And Barriers210
11.6spain 211
11.6.1forecast211
11.6.2key Events214
11.6.3drivers And Barriers214
11.7united Kingdom215
11.7.1forecast215
11.7.2key Events218
11.7.3drivers And Barriers218
11.8japan221
11.8.1forecast221
11.8.2key Events224
11.8.3drivers And Barriers224
11.9china227
11.9.1forecast227
11.9.2key Events229
11.9.3drivers And Barriers229
11.10india231
11.10.1forecast231
11.10.2key Events233
11.10.3drivers And Barriers233
12appendix234
12.1bibliography234
12.2abbreviations248
12.3methodology250
12.4forecasting Methodology250
12.4.1diagnosed Psoriasis Patients250
12.4.2percent Drug-treated Patients251
12.4.3drugs Included In Each Therapeutic Class251
12.4.4launch And Patent Expiry Dates252
12.4.5general Pricing Assumptions253
12.4.6individual Drug Assumptions254
12.4.7generic Erosion256
12.4.8pricing Of Pipeline Agents258
12.5physicians And Specialists Included In This Study259
12.6primary Research – Prescriber Survey260
12.7about The Authors261
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

7. 12.7.1analysts261
12.7.2epidemiologist262
12.7.3reviewers263
12.7.4global Director Of Epidemiology And Clinical Trials Analysis264
12.7.5global Head Of Healthcare264
12.8about Globaldata265
12.9contact Us265
12.10disclaimer265
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022